Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.

Ahn IE, Basumallik N, Tian X, Soto S, Wiestner A.

Blood. 2019 May 30;133(22):2452-2455. doi: 10.1182/blood.2019896688. Epub 2019 Mar 27. No abstract available.

PMID:
30917955
2.

Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.

Taneja A, Jones J, Pittaluga S, Maric I, Farooqui M, Ahn IE, Wiestner A, Sun C.

Leuk Lymphoma. 2019 Feb;60(2):519-522. doi: 10.1080/10428194.2018.1480775. Epub 2018 Jul 6. No abstract available.

PMID:
29978754
3.

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.

Robinson HR, Qi J, Cook EM, Nichols C, Dadashian EL, Underbayev C, Herman SEM, Saba NS, Keyvanfar K, Sun C, Ahn IE, Baskar S, Rader C, Wiestner A.

Blood. 2018 Aug 2;132(5):521-532. doi: 10.1182/blood-2018-02-830992. Epub 2018 May 9.

4.

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.

Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, Lotter J, Housel S, Stetler-Stevenson M, Yuan CM, Maric I, Calvo KR, Nierman P, Hughes TE, Saba NS, Marti GE, Pittaluga S, Herman SEM, Niemann CU, Pedersen LB, Geisler CH, Childs R, Aue G, Wiestner A.

Blood. 2018 May 24;131(21):2357-2366. doi: 10.1182/blood-2017-12-820910. Epub 2018 Feb 26.

5.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A.

J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4.

6.

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia.

Ahn IE, Farber CM, Davids MS, Grinblatt DL, Kay NE, Lamanna N, Mato A, Nabhan C, Kiselev P, Swern AS, Flick ED, Sullivan K, Sharman JP, Flowers CR.

Blood Adv. 2017 Nov 28;1(25):2433-2443. doi: 10.1182/bloodadvances.2017011262. eCollection 2017 Nov 28.

7.

Safety profiles of novel agent therapies in CLL.

Ahn IE, Davids MS.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):354-357. doi: 10.1182/asheducation-2017.1.354. Review.

8.

Controversies in multiple myeloma: Evidence-based update.

Ahn IE, Mailankody S.

Semin Oncol. 2016 Dec;43(6):666-675. doi: 10.1053/j.seminoncol.2016.10.006. Epub 2016 Nov 2. Review.

PMID:
28061984
9.

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

Ahn IE, Underbayev C, Albitar A, Herman SE, Tian X, Maric I, Arthur DC, Wake L, Pittaluga S, Yuan CM, Stetler-Stevenson M, Soto S, Valdez J, Nierman P, Lotter J, Xi L, Raffeld M, Farooqui M, Albitar M, Wiestner A.

Blood. 2017 Mar 16;129(11):1469-1479. doi: 10.1182/blood-2016-06-719294. Epub 2017 Jan 3.

10.

Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.

Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J.

Blood. 2016 Oct 13;128(15):1940-1943. Epub 2016 Aug 8.

11.

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.

Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA.

Haematologica. 2016 Jun;101(6):e254-8. doi: 10.3324/haematol.2015.138289. Epub 2016 Mar 24. No abstract available.

12.

Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients.

Wu SP, Pfeiffer RM, Ahn IE, Mailankody S, Sonneveld P, van Duin M, Munshi NC, Walker BA, Morgan G, Landgren O.

Clin Cancer Res. 2016 Aug 15;22(16):4039-44. doi: 10.1158/1078-0432.CCR-15-2366. Epub 2016 Feb 4.

13.

Dilemmas in treating smoldering multiple myeloma.

Ahn IE, Mailankody S, Korde N, Landgren O.

J Clin Oncol. 2015 Jan 1;33(1):115-23. doi: 10.1200/JCO.2014.56.4351. Epub 2014 Nov 24. Review.

14.

Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide.

Ahn IE, Natelson E, Rice L.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S300-4. doi: 10.1016/j.clml.2013.05.015.

PMID:
24290215
15.

Temporal differential effects of proinflammatory cytokines on osteoclastogenesis.

Moon SJ, Ahn IE, Jung H, Yi H, Kim J, Kim Y, Kwok SK, Park KS, Min JK, Park SH, Kim HY, Ju JH.

Int J Mol Med. 2013 Apr;31(4):769-77. doi: 10.3892/ijmm.2013.1269. Epub 2013 Feb 5.

16.

Periarticular osteoporosis is a prominent feature in early rheumatoid arthritis: estimation using shaft to periarticular bone mineral density ratio.

Moon SJ, Ahn IE, Kwok SK, Park KS, Min JK, Park SH, Kim HY, Ju JH.

J Korean Med Sci. 2013 Feb;28(2):287-94. doi: 10.3346/jkms.2013.28.2.287. Epub 2013 Jan 29.

17.

Upregulation of stromal cell-derived factor by IL-17 and IL-18 via a phosphatidylinositol 3-kinase-dependent pathway.

Ahn IE, Ju JH, Lee SY, Park JS, Oh HJ, Kim HR, Lee SH, Park SH, Kim HY, Cho ML.

Scand J Immunol. 2012 Oct;76(4):433-9. doi: 10.1111/j.1365-3083.2012.02745.x.

18.

Cost analysis of asymmetric sensorineural hearing loss investigations.

Wilson YL, Gandolfi MM, Ahn IE, Yu G, Huang TC, Kim AH.

Laryngoscope. 2010 Sep;120(9):1832-6. doi: 10.1002/lary.20933.

PMID:
20661936
19.

The silent progression of metastatic malignancy during the treatment with soluble tumor necrosis factor receptor.

Ahn IE, Ju JH, Kang KY, Park SH, Kim HY.

Clin Rheumatol. 2010 Feb;29(2):225-7. doi: 10.1007/s10067-009-1306-9. Epub 2009 Nov 7.

PMID:
19898739
20.

Radiologic observation: repair of focal bone erosions after humanized antitumor necrosis factor antibody adalimumab therapy in a patient with rheumatoid arthritis.

Ahn IE, Ju JH, Park SH, Kim HY.

Clin Rheumatol. 2010 Feb;29(2):211-3. doi: 10.1007/s10067-009-1293-x. Epub 2009 Oct 7.

PMID:
19809777

Supplemental Content

Support Center